Trump Fires AG Bondi: What the DOJ Shakeup Means for Cannabis Rescheduling

In a stunning move on April 2, 2026, President Trump fired Attorney General Pam Bondi, reshaping the Department of Justice leadership just as the cannabis industry watched anxiously for progress on marijuana rescheduling. Deputy Attorney General Todd Blanche assumes the role of acting attorney general, while EPA Administrator Lee Zeldin is reportedly under consideration for the permanent position.

The question on everyone's mind in the cannabis sector: Does this leadership change accelerate, delay, or fundamentally alter the timeline for moving cannabis from Schedule I to Schedule III?

The short answer: Industry sources say rescheduling remains on track, likely within the next 30 to 60 days. But the personnel shuffle underscores just how volatile—and pivotal—the current moment is for federal marijuana policy.

Why Trump Fired Bondi: A Perfect Storm

Bondi's tenure as Attorney General was marked by rising friction with the President. According to multiple reports, Trump grew "more and more frustrated" with his AG over several intersecting issues. The frustrations extended beyond cannabis policy to include disputes over the handling of Epstein files and various political prosecutions that didn't align with the President's priorities.

But the cannabis rescheduling delays clearly rankled Trump. Back in December 2025, Trump issued an executive order explicitly directing Bondi to expedite marijuana rescheduling efforts. For an administration that positioned itself as pro-cannabis reform, the pace of progress apparently felt glacial to the President.

Bondi faced a difficult balancing act. While her boss wanted faster action on rescheduling, the underlying bureaucratic machinery—DEA rulemaking, legal review processes, and interagency coordination—moved at its own pace. The gap between Trump's expectations and the real-world timeline for federal drug policy change likely contributed to the tension that ultimately led to her dismissal.

Todd Blanche Steps In: Continuity with Momentum

Now comes Todd Blanche as acting attorney general. For cannabis advocates and industry stakeholders, Blanche's appointment carries a crucial advantage: he's already familiar with the rescheduling issue.

Trent Woloveck, a Jushi Holdings executive, described Blanche as "a big net positive" for the cannabis industry. That's significant insider validation from a major multistate operator. Blanche's prior exposure to cannabis policy means there's no learning curve at a critical juncture.

The appointment of an acting AG who understands the cannabis file also signals continuity at a sensitive moment. Rather than a complete reset, the DOJ's cannabis agenda appears positioned to maintain momentum. Blanche isn't walking in cold; he understands what needs to happen and why.

The big question: As acting AG, does Blanche have the authority and political cover to keep the DEA rulemaking process moving at the accelerated pace Trump expects? History suggests that acting leadership can sometimes move faster than confirmed leaders, unencumbered by some of the political calculations that come with Senate confirmation. That could work in favor of cannabis rescheduling.

Lee Zeldin's Potential Role: A More Complex Cannabis Record

While Blanche holds the reins in an acting capacity, EPA Administrator Lee Zeldin is reportedly under serious consideration for the permanent attorney general role. That's where the story gets more complicated.

Zeldin's voting record on cannabis is decidedly mixed, which should concern those hoping for aggressive federal rescheduling advocacy.

On the positive side, Zeldin voted for 2015 amendments that protected state medical cannabis programs from federal interference. He also supported legislation allowing Department of Veterans Affairs doctors to issue cannabis recommendations to patients. These votes suggest some openness to federalism-based cannabis policy and medical access.

But Zeldin's opposition to medical cannabis in 2014, when he was a New York state senator, reveals a different chapter of his record. That's a more recent vote showing skepticism about broader cannabis legalization or medical access. His evolution on cannabis policy isn't entirely clear, and it's far from the unambiguous pro-reform stance that the cannabis industry might hope for in a permanent attorney general.

If Zeldin is confirmed as AG, the administration would be signaling that cannabis rescheduling is proceeding, but perhaps with a more measured, federalism-respecting approach rather than sweeping federal legalization advocacy. That may or may not be satisfactory to the broader cannabis reform movement.

The DEA Rulemaking Process Continues

Regardless of who occupies the attorney general's office, the actual rescheduling mechanism grinds forward through the DEA's official rulemaking process. This is the crucial procedural reality that often gets lost in headlines about personnel changes.

The DEA is in the midst of formal rulemaking to reschedule cannabis from Schedule I to Schedule III. This process involves scientific review, public comment periods, coordination with other agencies, and ultimately a formal notice of proposed rulemaking. It's bureaucratic, it's deliberate, but it's also moving.

Trump's executive order in December created a deadline and a political imperative, but it didn't eliminate the procedural steps. Bondi's firing was partly a signal of the President's impatience with those timelines. Blanche's appointment, however, signals that the administration intends to keep pressure on the DEA to meet them.

Industry insiders and policy observers consistently indicate that rescheduling is expected within 30 to 60 days. That suggests the DEA rulemaking is sufficiently advanced that the major delays aren't ahead—they're behind. The next phase is formal announcement and implementation.

What This Means for Multistate Operators and the Broader Industry

For cannabis companies, the personnel changes at DOJ are significant precisely because they could affect the pace of rescheduling—but most analysis suggests the pace is accelerating rather than slowing.

Moving cannabis from Schedule I to Schedule III would be transformative for the industry. It would unlock banking access, reduce federal tax burdens, and create opportunities for multi-state operators to consolidate and scale more easily. It would also provide clearer regulatory pathways for research and development.

The appointment of an acting AG who's already familiar with the rescheduling agenda is a net positive for timeline certainty. Blanche isn't walking in cold; he understands what needs to happen and why.

Zeldin's potential permanent appointment introduces more ambiguity, but his past votes on medical cannabis and state protections suggest he's unlikely to obstruct rescheduling once it's formally proposed.

The Bottom Line: Momentum Preserved

Pam Bondi's firing feels dramatic, and in some ways it is. It reflects the Trump administration's frustration with the pace of change on cannabis and other issues. But the firing also clears away a potential bottleneck and installs an acting AG with prior knowledge of the rescheduling file.

The Department of Justice shakeup, rather than disrupting cannabis rescheduling, appears positioned to accelerate it. That's the consensus from industry observers who've studied the personnel dynamics and the DEA's procedural timeline.

Within the next 30 to 60 days, expect to see formal action from the federal government on cannabis scheduling. The question isn't whether it happens, but how smoothly the bureaucratic machinery turns now that Trump has removed a perceived obstacle from the attorney general's office.

For an industry that's waited decades for federal policy to catch up with state-level reality, that's genuinely encouraging news.